10x Genomics $TXG Shares Sold by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. decreased its stake in 10x Genomics (NASDAQ:TXG) by 55.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 274,440 shares of the company’s stock after selling 340,854 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in 10x Genomics were worth $3,208,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of TXG. Foundations Investment Advisors LLC acquired a new stake in shares of 10x Genomics during the 3rd quarter worth approximately $665,000. Jump Financial LLC increased its stake in 10x Genomics by 130.2% during the 2nd quarter. Jump Financial LLC now owns 1,041,051 shares of the company’s stock worth $12,055,000 after buying an additional 588,769 shares during the period. AlphaQuest LLC increased its holdings in 10x Genomics by 234.3% during the 3rd quarter. AlphaQuest LLC now owns 133,419 shares of the company’s stock worth $1,560,000 after purchasing an additional 93,514 shares during the period. Friedenthal Financial acquired a new stake in 10x Genomics in the third quarter valued at approximately $924,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of 10x Genomics in the 3rd quarter valued at $1,179,000. Hedge funds and other institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Performance

Shares of NASDAQ TXG opened at $18.89 on Tuesday. The firm has a market cap of $2.41 billion, a price-to-earnings ratio of -53.97 and a beta of 2.24. The stock’s 50-day simple moving average is $18.92 and its 200-day simple moving average is $15.86. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $23.56.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Thursday, February 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.06. 10x Genomics had a negative return on equity of 6.89% and a negative net margin of 6.77%.The company had revenue of $166.03 million during the quarter, compared to analyst estimates of $160.35 million. During the same quarter last year, the firm earned ($0.40) EPS. The business’s revenue was up .6% on a year-over-year basis. As a group, research analysts predict that 10x Genomics will post -1.43 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Bank of America set a $21.00 target price on shares of 10x Genomics in a research report on Monday, January 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research report on Monday, December 22nd. JPMorgan Chase & Co. increased their target price on 10x Genomics from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Canaccord Genuity Group set a $22.00 price objective on shares of 10x Genomics in a research note on Friday, February 13th. Finally, TD Cowen raised their price target on 10x Genomics from $18.00 to $19.00 and gave the company a “hold” rating in a research report on Friday, February 13th. Four equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, 10x Genomics presently has a consensus rating of “Hold” and an average price target of $18.11.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.